Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

NYSE:BTX opened at $2.24 on Friday. The company has a market cap of $131.77 million, a price-to-earnings ratio of -0.99 and a beta of 4.61. The stock’s fifty day moving average price is $2.13 and its two-hundred day moving average price is $1.81. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10.

Institutional Trading of Brooklyn ImmunoTherapeutics

A hedge fund recently raised its stake in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC lifted its holdings in shares of Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) by 20.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,459,626 shares of the company’s stock after purchasing an additional 243,826 shares during the quarter. Renaissance Technologies LLC owned 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 at the end of the most recent quarter. 26.00% of the stock is currently owned by hedge funds and other institutional investors.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.